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Abstract
Background: The patho-mechanisms leading to brain damage due to cerebral malaria (CM) are
yet not fully understood. Immune-mediated and ischaemic mechanisms have been implicated. The
role of complement factors C1q, C3 and C5 for the pathogenesis of CM were investigated in this
study.
Methods: C57BL/6J mice were infected with Plasmodium berghei ANKA blood stages. The clinical
severity of the disease was assessed by a battery of 40 standardized tests for evaluating neurological
functions in mice. Brain homogenates and sera of mice with CM, infected animals without CM and
non-infected control animals were analyzed for C1q, C3 and C5 up-regulation by Western blotting.
Results:  Densitometric analysis of Western blots of brain homogenates yielded statistically
significant differences in the levels of C1q and C5 in the analyzed groups. Correlation analysis
showed a statistically significant association of C1q and C5 levels with the clinical severity of the
disease. More severely affected animals showed higher levels of C1q and C5. No differences in
complement levels were observed between frontal and caudal parts of the brain. Densitometric
analysis of Western blot of sera yielded statistically lower levels of C1q in infected animals without
CM compared to animals of the control group.
Conclusion: The current study provides direct evidence for up-regulation of complement factors
C1q and C5 in the brains of animals with CM. Local complement up-regulation is a possible
mechanism for brain damage in experimental cerebral malaria.
Background
Cerebral malaria (CM) is a major cause of morbidity and
mortality of Plasmodium falciparum malaria. It presents as
a diffuse encephalopathy with alteration of conscious-
ness, ranging from drowsiness to deep coma and is fre-
quently accompanied by seizures [1]. Mortality is high
and neurological sequelae are observed in approximately
10% of the survivors [2]. The pathophysiological mecha-
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nisms of CM are not yet fully understood. Most research-
ers agree that the immune response of the host is a critical
factor in the pathogenesis of CM. Different aspects have
been studied and in particular pro-inflammatory
cytokines and activated T-lymphocytes have been shown
to be related to the development of CM [3,4]. One potent
stimulator of inflammation is the complement system. It
consists of about 30 fluid-phase and cell-membrane pro-
teins and is important not only to recognize but also kill
pathogens such as bacteria, virus infected cells and para-
sites, while preserving normal 'self' cells. Complement
can be activated by two distinct routes, the classical and
the alternative pathway. The classical pathway is activated
primarily by the interaction of C1q with immune com-
plexes (antibody-antigen). The alternative pathway is trig-
gered directly on pathogen surfaces and leads to the
deposition of C3 fragments (opsonins) on the target cells.
The ultimate goal for the activation of the complement
system is the formation of the membrane attack complex
which is initiated by proteolytical cleavage of C5 and dis-
rupts the phospholipid bilayer to lyse the target cell [5].
In addition, the small complement fragments C3a, C4a
and C5a, the so-called anaphylatoxins act on specific
receptors to produce local inflammatory responses. They
are released in the fluid phase during complement activa-
tion after enzymatic cleavage of C3 and C5. These factors
are acting directly on blood vessels, stimulating an
increase in blood flow, increasing vascular permeability
and increase the binding of phagocytes to endothelial
cells [5]. C5a also activates mast cells to release mediators
such as histamine and TNF-alpha that contribute to the
inflammatory response [6]. While data on complement
factors in neuroinflammation in CM is still limited, some
reports show the important role of complement factors in
systemic inflammatory response to murine malaria infec-
tion [7,8].
Besides its potential to induce a marked local inflamma-
tion the pro-apoptotic capacity of C5a in neurons is of
interest [9,10] since apoptosis has been shown to be an
important neuropathological feature of murine CM
[11,12]. A further focus in the pathophysiology of murine
CM is the integrity of the blood-brain barrier (BBB) [13].
BBB dysfunction may allow the influx of cytokines,
malaria antigens and complement into the brain. C1q has
been reported to have a role in BBB breakdown in an
experimental BBB disintegration model [14]. C1q is pro-
duced by microglia and astrocytes. Activation of both cell
types precedes clinical symptoms of CM [15,16]. Impor-
tantly, increased gene-expression of C1q is found in the
brains of CM susceptible mice, as compared to animals
resistant to CM, in Plasmodium berghei infection [17]. In
addition, C1q, beside anaphylatoxins, is able to trigger a
proinflammatory immune response by inducing
cytokines and chemokines and activation of neutrophils
and eosinophils [18].
Although it has been shown that genes of identified com-
plement-related function are induced during murine CM
[19], data on protein expression of complement factors in
the murine brain are missing. The current study was con-
ducted to analyze complement factors C1q, C3 and C5 –
catalyzing crucial steps in the complement cascade – in
the brains and sera of mice infected with Plasmodium
berghei ANKA – a well-established model of cerebral
malaria.
Methods
Animals and sample preparation
Nineteen 6 to 8 weeks old C57BL/6J mice (Charles River,
Sulzfeld, Germany) were used for this study. Fifteen ani-
mals were infected intraperitoneally with 5.106 parasit-
ized red blood cells of a homologue donor, which had
been infected with frozen polyclonal stocks of P. berghei
ANKA. Parasitaemia was monitored every other day. The
clinical severity of the disease was assessed by the SHIRPA-
score primary screen to discriminate different levels of
severity in murine CM [20]. The primary screen comprises
a battery of 40 simple tests for evaluating neuromuscular,
spinocerebellar, sensory, neuropsychiatric and autonomic
functions in mice by observational assessment. The scor-
ing starts with the evaluation of undisturbed behavior in
a viewing jar. Subsequently the mouse is transferred to an
arena for observation of motor behaviour. Afterwards a
sequence of manipulations using tail suspension is per-
formed and visual acuity, grip strength, body tone and
reflexes are recorded. Finally autonomous functions like
skin color and heart rate are assessed in supine restraint
and the procedure is ended with measurement of rectal
body temperature. All test values are then summed up and
the cumulative SHIRPA-score is calculated as described
previously [20]. Healthy mice show a value of about 30,
while moribund CM animals show values of about 10.
Animals at different clinical stages of the disease were
killed and further processed for Western blot analysis.
Four non-infected C57BL/6J mice (CNT) and three
infected animals that did not develop CM (NCM) served
as controls. All animals were given a lethal dose of 0.5 ml
(25 mg/ml) thiopental (Biochemie, Kundl, Austria) intra-
peritoneally. Deeply anesthetized mice (total n = 19, CM
n = 12, NCM n = 3, CNT n = 4) were transcardially per-
fused with PBS for 2 min with a pressure controlled
syringe pump (Fresenius-Kabi, Bad Homburg, Germany).
Mouse serum was harvested immediately before per-
fusion by puncture of the right cardiac ventricle. Animal
studies conformed to the Austrian guidelines for the care
and use of laboratory animals and were approved by the
Austrian Government.Malaria Journal 2008, 7:207 http://www.malariajournal.com/content/7/1/207
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Western Blot
Pivotal complement factors C1q, C3 and C5 were ana-
lyzed in protein balanced brain homogenates and sera of
mice with different clinical levels of severity of CM (CM,
n = 12), infected animals without neurological affection
(NCM, n = 3) and non-infected control animals (CNT, n
= 4). Samples of frontal (cerebrum) and caudal (brain
stem and cerebellum) parts of the brain were processed
separately. The microdissected tissue was homogenized in
ice-cold buffer (pH 7.5) containing 50 mM Tris-Cl, 5 mM
EDTA, 50 mM NaCl, 5 mM DTT, 0.1% Np-40, 50 mM
NaF, 1 mM PMSF, 1 mM Na3VO4 plus a protease inhibitor
cocktail (Roche, Mannheim, Germany) and centrifuged at
18500 g for 20 min at 4°C. Protein-balanced samples
were analyzed using standard techniques. Antibodies
were diluted in blocking solution (2% milk powder in
PBS). Bottom and top parts of the blots were probed with
monoclonal antibodies, C1q-a (M-120, Santa Cruz Bio-
technology, Santa Cruz, USA; 1:1,000 in blocking solu-
tion) and C5 (Dako, Glostrup, Denmark; 1:2,000 in
blocking solution) overnight at 4°C. To control and cor-
rect for equal loading, the middle part of each blot was
probed for alpha-tubulin (Sigma, St. Louis, USA; 1:40,000
in blocking solution) overnight at 4°C. Antibody binding
was visualized using enhanced chemoluminescence rea-
gents (Lumiglo™; Boston, USA, Cell Signaling). After film
development, antibodies were stripped in stripping solu-
tion (pH 8.8) containing 1 M Tris, 10% SDS, 0.5% 2-mer-
captoethanol in a water bath at 70°C for 20 minutes. After
rinsing in PBS-T (PBS containing 0.1% Triton-X 100) for
45 minutes the top part of the blot was probed with a pol-
yclonal antibody C3 (H-300, Santa Cruz Biotechnology,
1:1000 in blocking solution), which detects full length
and the alpha-subunit (110 kD) of C3. Antibody binding
was visualized using enhanced chemoluminescence rea-
gents (Lumiglo™; Cell Signaling).
Statistical methods
Densitometric values of complement factors C1q, C3 and
C5 of frontal and caudal parts of the brain were compared
using Wilcoxon signed rank sum test. Since there was no
statistical difference between the data of the respective
brain areas, the mean values between frontal and caudal
parts of the brain were calculated and used for further
analyses. Kruskal-Wallis test and Dunn's post test were
used to analyze complement levels in the different disease
groups. Spearman's rho was calculated between the cumu-
lative SHIRPA-score and the densitometric values of C1q,
C3 and C5. Calculations were done using Insightful S-Plus
6.2 (Insightful Corporation, Seattle, WA, USA), graphs
were drawn with GraphPad Prism 5.00 (GraphPad Soft-
ware, San Diego, USA).
Results
Twelve of the 15 infected animals developed signs of CM
between day-5 and day-7 post-infection (day-5 n = 2; day-
6 n = 7; day-7 n = 3) with low levels of parasitaemia
between 5% and 15% (CM group). Animals with CM
were divided into three CM severity groups for further
analysis according to the SHIRPA-score (mild: CM1 =
SHIRPA-score >25; moderate: CM2 = SHIRPA-score 15–
25; severe: CM3 = SHIRPA-score < 15). The mean body
temperature was 37.6 (CM1), 31.9 (CM2) and 28.7
(CM3) degree Celsius in the respective groups. Three ani-
mals survived the CM vulnerable period and were killed at
day-11 post-infection. Since these mice did not show neu-
rological signs they served as an additional control group
(NCM group). Parasitaemia levels in the early course of
the infection were highly similar between the two groups.
Comparing the densitometric values of C1q, C3 and C5 in
homogenates from frontal (cerebrum) and caudal (brain
stem and cerebellum) parts of the brain in mice with CM
did not yield significant differences.
C1q is significantly higher in brain homogenates of mice 
with CM
C1q levels in brain homogenates showed a statistically
significant difference in the analyzed groups (Figures 1A
and 2A; Kruskal-Wallis test; p < 0.05). Post-hoc analysis
did not show significant differences between the respec-
tive groups of interest. In mice with CM, Spearmen's Rho
indicated a significant correlation of C1q complement
values in brain homogenates and the clinical severity
score (Figure 4A; rho = -0.64, p < 0.05), i.e. animals with
more severe disease showed higher levels of brain C1q.
Densitometric measures of C1q in sera of the studied ani-
mals revealed a statistically significant difference (Figure
3A). Post hoc analysis yielded significantly lower values in
NCM animals compared to non infected control animals
(Figures 1G and 3A).
C3 levels are not altered during the course of murine CM
No significant alterations of complement levels of C3 in
brains or sera were found in the analyzed groups (Figures
1C, 1H and 2B). In mice with CM there was no significant
correlation between brain complement levels and the
cumulative SHIRPA-score.
C5 is significantly higher in brain homogenates of mice 
with CM
C5 levels in brain homogenates showed a statistically sig-
nificant difference in the analyzed data groups (Figures 1E
and 2C; Kruskal-Wallis test; p < 0.05). Post-hoc analysis
showed significantly higher levels of C5 in animals with
moderate (CM2) and severe CM (CM3) as compared to
non-infected control animals (CNT). In mice with CM,
Spearmen's rho indicated a significant correlation of C5
complement values in brain homogenates and the clinicalMalaria Journal 2008, 7:207 http://www.malariajournal.com/content/7/1/207
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Representative Western blot experiments of complement factors C1q (A), C3 (C) and C5 (E) in brains and in sera (G-I) of ani- mals with different clinical levels of severity of cerebral malaria (CM1-3), infected animals without CM (NCM) and non infected  control animals (CNT) Figure 1
Representative Western blot experiments of complement factors C1q (A), C3 (C) and C5 (E) in brains and in 
sera (G-I) of animals with different clinical levels of severity of cerebral malaria (CM1-3), infected animals with-
out CM (NCM) and non infected control animals (CNT). Alpha-tubulin (B, D, F). (+) = positive control.Malaria Journal 2008, 7:207 http://www.malariajournal.com/content/7/1/207
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Densitometric analysis of Western blots of complement factors C1q (A), C3 (B) and C5 (C) in brain homogenates of animals  with different clinical levels of disease severity (CM1-3, n = 12), infected animals without CM (NCM, n = 3) and non-infected  control animals (CNT, n = 4) Figure 2
Densitometric analysis of Western blots of complement factors C1q (A), C3 (B) and C5 (C) in brain homoge-
nates of animals with different clinical levels of disease severity (CM1-3, n = 12), infected animals without CM 
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Densitometric analysis of Western blots of complement factors C1q (A), C3 (B) and C5 (C) in sera of animals with different  clinical levels of severity of cerebral malaria (CM1-3, n = 12), infected animals without CM (NCM, n = 3) and non-infected con- trol animals (CNT, n = 4) Figure 3
Densitometric analysis of Western blots of complement factors C1q (A), C3 (B) and C5 (C) in sera of animals 
with different clinical levels of severity of cerebral malaria (CM1-3, n = 12), infected animals without CM 
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severity score (Figure 4B; rho = -0.73, p < 0.01), i.e. ani-
mals with more severe disease showed higher levels of
brain C5. Densitometric measures of C5 in sera of the
studied animals revealed no statistically significant differ-
ences (Figure 3C).
Discussion
In the present study, the dynamics of complement factors
C1q, C3 and C5 in the brains and sera of mice with
malaria were investigated. Statistically significant direct
correlations of C1q and C5 levels in brains of CM animals
with disease severity were found. In sera of infected ani-
mals without CNS involvement C1q levels were signifi-
cantly lower than in non infected controls.
Only limited data on the regulation of complement fac-
tors in the brain during experimental CM exists. In a
recent observation by Delahaye et al gene expression of
C1q was increased in the brains of CM susceptible mice,
compared to resistant ones. In the present study, protein
levels of C1q were elevated in animals with severe CM.
This could be contributed to increased local production of
C1q. Pro-inflammatory cytokines (in particular TNF-
alpha and IFN-gamma) are capable to induce expression
of complement factors in brain parenchymal cells in vitro
[21]. Gene-levels of pro-inflammatory cytokines have
been shown to be up-regulated in brain tissue during CM
[22] and recently Interferon responsive mechanisms were
reported to be of critical importance to the susceptibility
to experimental CM [19]. Further, microglia is the most
abundant source of C1q in the brain [23] and microglia
induction has been shown to be a feature of the early
course of murine CM [16]. Noteworthily, the blood brain
barrier is known to be impaired in murine CM and sys-
temic leakage of C1q into the brain could also lead to the
elevated C1q levels in brain homogenates. However, the
normal or even reduced levels of C1q in sera of mice with
CM taken together with the reported increase in C1q gene
transcription during CM might indicate local production
of C1q. These findings warrant further studies on the exact
source of complement production in the murine brain
during CM.
This is of importance since the complement system, when
activated at an inappropriate site and/or to an inappropri-
ate extent, is remarkably effective in damaging host tissues
thereby causing pathological changes, as seen in degener-
ative and inflammatory disorders of the central nervous
system [24]. To avoid damage by complement, host cells
are usually protected by a battery of regulatory molecules,
which inhibit assembly of the membrane attack complex
and subsequent lysis of the host cell. However, it has been
shown that C1q binds specifically to the membrane of
neurons and leads to the activation of the classical path-
way in an antibody-independent manner [25]. Therefore,
one can speculate that direct damage to neurons by C1q
mediated induction of the classical complement pathway
with consecutive cell lysis might contribute to neu-
ropathological changes seen in murine CM [26].
Another important pathophysiological mechanism of
brain damage in murine CM is neuronal apoptosis
[11,12]. It has been shown that neurons have the capabil-
ity of expressing the C5a receptor which in turn can
induce apoptosis after binding to its ligand C5a [10].
Importantly, the C5a receptor is up-regulated in different
inflammatory diseases of the central nervous system [27],
Correlation analysis of densitometric values of C1q (A) and  C5 (B) and the clinical severity of the disease (SHIRPA-score)  in animals with CM (n = 12) Figure 4
Correlation analysis of densitometric values of C1q 
(A) and C5 (B) and the clinical severity of the disease 
(SHIRPA-score) in animals with CM (n = 12). Spear-
man's rho and p-value are shown.
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hence the marked increase of C5 in the present study
could represent another source of neurodegenerative
potential in murine CM. Interestingly, a previous study
showed that apoptosis in the murine brain during CM was
mainly observed in neurons and oligodendrocytes and to
a much lesser extent in astrocytes and microglia [11]. The
latter cells express surface as well as soluble inhibitors of
complement [5] thereby rendering them less susceptible
to C5a induced apoptosis. Indeed oral administration of
C5a receptor antagonists reduces neuronal apoptosis and
protects rats from 3-nitropropionic acid (3-NP)-induced
Huntington's disease [28]. Furthermore, C5 deficiency
and C5a or C5aR blockade protects mice infected with
Plasmodium berghei ANKA against cerebral malaria [29].
Therefore, such agents represent promising candidates for
adjunctive neuroprotective/immunomodulatory treat-
ment of CM.
C5a is a potent anaphylatoxin which is known to induce
the production of proinflammatory cytokines and hista-
mine and to promote the expression of adhesion mole-
cules on endothelial cells [6,30,31]. Histamine has
recently been shown to be of critical importance to the
neuropathology of CM and histamin-decarboxylase defi-
cient mice were protected from CM [32]. Further, ICAM-1
is upregulated during murine CM and leukocyte seques-
tration to the brain endothelia is also linked to neuropa-
thology [4,33,34]. It should be noted that in the current
study, due to its central role to the complement cascade,
full length C5 was investigated, hence, the implication of
its breakdown product C5a in murine CM remains to be
resolved.
Another important finding of this study is the lack of spa-
tial differences in the levels of complement factors C1q,
C3 and C5 between the frontal (cerebrum) and caudal
parts (brain stem and cerebellum) of the brain. This is of
particular interest since these findings are in contrast to
previous observations by our group and others in which
the brain stem was the primary focus of neuronal apopto-
sis and microhaemorrhages [11,20,35]. This indicates that
factors other than complement activation are responsible
for the selective vulnerability of this brain region.
The levels of C1q in sera of animals with CM were normal
or even lower than those in CNT animals. Further,
infected mice without neurological affection (NCM)
showed significantly lower levels of C1q. This is in line
with the observation that C1q hypocomplementemia
along with increased levels of immune complexes were
observed in the sera of humans with P. falciparum malaria
[36]. In addition it was demonstrated that free haem
inhibits the function of C1q [37]. Therefore, not only con-
sumption of C1q due to immune complex elimination
but also direct inhibition or down-regulation of C1q by
free haem can be regarded as a contributor to the reduced
C1q levels in NCM mice in the present study.
Conclusion
In conclusion, the current data provides evidence for the
induction of the complement cascade in the brains of
mice with CM. This suggests a role of complement factors
C1q and C5 in the neuropathology of CM and emphasizes
the importance of the host immune response in this
neuro-infectious disease. Further studies on complement
are warranted in order to confirm the pathophysiological
role of these factors in CM. This might open a new per-
spective for adjunctive therapeutical approaches targeting
the innate immune system.
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